Pulmonary Arterial Hypertension Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Pulmonary Arterial Hypertension Market is segmented By Drug Class (Prostacyclin and Prostacyclin Analogs, Calcium Channel Blockers, Phosphodiesterase 5 (PDE-5), Endothelin Receptor Antagonists (ERA), and Others), By Route of Administration (Inhalation, Injectable and Oral Administration), By Distribution channel (Hospital Pharmacy, Pharmacy stores, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Pulmonary Arterial Hypertension Market Overview

The Global Pulmonary Arterial Hypertension Market size was worth USD 7 billion in 2022 and is estimated to reach USD 10.6 billion by 2030, growing at a CAGR of 5.3% during the forecast period 2024-2031.  Pulmonary arterial hypertension (PAH) is a subtype of pulmonary hypertension, which is defined as excessive blood pressure in the lungs. 

This elevated pressure in the vasculature in PAH is produced by a number of obstructions in the tiny arteries of the lung.

Pulmonary arterial hypertension (PAH) is more frequent in women aged 30-60. Although there is no cure for PAH, therapies are available to reduce symptoms and enhance quality of life. PAH is classified as Group 1. Every year, 500-1000 new cases of PAH are detected in the United States.

Pulmonary Arterial Hypertension Market Scope

To Know more Insights - Download Sample

Pulmonary Arterial Hypertension Market Dynamics

Increase in Prevalence of Pulmonary Artery Hypertension 

Increased prevalence of pulmonary artery hypertension is a key driver for the pulmonary arterial hypertension market. For instance  according to recent study , the overall incidence of pulmonary arterial hypertension was 14 cases per million, higher than the Reveal registry, odds ratio 6.3 (95% CI: 4.2-9.5), (p.001).  

The annual period prevalence of pulmonary arterial hypertension was 93 cases per million, which was also higher than the REVEAL, odds ratio = 7.5 (95% CI: 6.4-8.8), and remained higher when the clinic cohort was limited to patients with hemodynamic severity comparable to the REVEAL, odds ratio = 3.8 (95% CI: 3.0-4.6), (p.001).

Side Effects of the drug used for treating Pulmonary Artrial Hypertension 

One of the restraints is the side effects of the drug used to treat pulmonary arterial hypertension. For instance, According to the American College of Cardiology, sotatercept reduces death and clinical worsening by 84% in pulmonary arterial hypertension. In phase 3, a randomized, double-blind, placebo-controlled STELLAR trial, the researchers randomly assigned 323 patients with WHO group I and WHO functional class II or III PAH taking background PAH therapy to sotatercept (Accutane). The initial dose was 0.3 mg/kg, followed by 0.7 mg/kg every 3 weeks.

For more details on this report - Request For Sample

Pulmonary Arterial Hypertension Market Segment Analysis

The Global Pulmonary Arterial Hypertension Market is segmented based on Drug class, Route of Administration and Distribution channel.

The Prostacyclin and Prostacyclin Analogues Drug Class Segment will be Dominated By Market Players During The Forecast Period. 

The prostacyclin and prostacyclin analogs drug class segment, with a percentage of around  39.6%, is dominated by market players during the forecast period. As prostacyclin and prostacyclin analogs significantly impact the Pulmonary Arterial Hypertension Market, where epoprostenol therapy improves cardiovascular variables, significantly reduces symptoms of breathlessness and tiredness, and increases exercise tolerance in individuals with PAH. Other advantages include lower total pulmonary resistance, lower pulmonary vascular resistance (PVR), lower mPAP, and higher cardiac index and stroke volume.

SGC simulators, on the other hand, are predicted to be the market's fastest-growing category. SGC stimulation promotes segment development by assisting in the modulation of physiological responses such as vascular smooth muscle, inflammatory suppression, and thrombosis.

Source: DataM Intelligence Analysis (2023)

Pulmonary Arterial Hypertension Market Geographical Penetration

North America is the dominating region during the forecast period.

North America is estimated to hold around 39.1% of the total market share throughout the forecast period. According to the American Lung Association, PAH is a rare and progressive disease that accounts for 500-1000 new cases identified in the United States annually. Furthermore, according to the same source, roughly 15-20% of PAH patients have heritable PAH caused by genetic alterations. Moreover, manufacturers are launching efforts to deliver knowledge and resources to healthcare practitioners, driving the market growth. For example, the United Therapeutics-supported PAH Initiative provides tools and information to help healthcare practitioners treat PAH patients.

Source: DataM Intelligence Analysis (2023)

Pulmonary Arterial Hypertension Market Players

The major global players include Arena Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Company, Gilead Sciences Inc, GlaxoSmithKline Plc, Actelion Pharmaceuticals, Ltd. (Johnson & Johnson), Merck & Co. Inc, Novartis International AG, Pfizer Inc, United Therapeutics Corporation

COVID-19 Impact on Pulmonary Arterial Hypertension Market 

COVID-19 has substantially influenced the Pulmonary Arterial Hypertension Market, where several risks linked with COVID-19 in patients with PAH are severe. The rate of COVID-19 infection in a US study of 77 PAH Comprehensive Care Centers was 2.1 instances per 1,000 patients with PAH, which is comparable to the prevalence of COVID-19 infection in the general US population. 

Although COVID-19 did not appear to be more frequent in PAH patients, death did appear to be greater at 12%. Furthermore, 33% of patients with PAH who were infected with COVID-19 were hospitalized. Since   COVID-19 predominantly affects the respiratory system, those who have pre-existing lung diseases like PAH may be more likely to have serious consequences if they get the virus. It is crucial to highlight.

By Drug Class

• Prostacyclin and Prostacyclin Analogs 
• Calcium Channel Blockers
• Phosphodiesterase 5 (PDE-5)
• Endothelin Receptor Antagonists (ERA)
• Others

By Route of Administration 

• Inhalation
• Injectable
• Oral Administration 

By Distribution Channel

• Hospital Pharmacy
• Pharmacy Stores 
• Others 

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Russia-Ukraine Conflict Analysis

Russia-Ukraine Conflict analysis disrupted the PAH market with many factors like Disruption of healthcare infrastructure: As a result of the direct impacts of combat, healthcare infrastructure in conflict-affected areas may be damaged or stressed. As a result, access to medical services, especially specialized centers competent to diagnose and treat PAH, may be limited.

Medication shortages: The war may interrupt the supply chain for crucial pharmaceuticals, especially those required to treat PAH. This might lead to drug shortages or problems in obtaining critical medicines, resulting in ineffective illness management.

Key Developments 

In May 2023 Sotatercept will be reviewed by the ICER for pulmonary arterial hypertension. The Institute for Clinical and Economic Review (ICER) announced that it would evaluate the clinical effectiveness and value of sotatercept, a new experimental first-in-class medication for pulmonary arterial hypertension (PAH).

Sotatercept acts by preventing abnormal signalling in the pulmonary blood arteries that results in an imbalance of growth inhibitory and growth promoting mediators, such as activins. As a result, it works against the mechanism of PAH, which causes constriction of tiny blood arteries in the lungs, limiting blood flow from the right side of the heart.

In May 2023 Gossamer Bio plans to begin a Phase 3 PAH study with seralutinib this year. Gossamer Bio intends to begin a Phase 3 clinical trial of their investigational inhaled medication seralutinib (GB002) in patients with pulmonary arterial hypertension (PAH) soon. We are on pace to start our Phase 3 clinical study of seralutinib in the coming months, taking us one step closer to our aim of providing a possible new treatment to PAH patients.

In April 2023, US Food and Drug Administration (USFDA) has certified Treprostinil injectable as a therapeutic comparable generic form of Remodulin. Dr. Reddy's new product is available in 20 mg/20 ml, 50 mg/20 ml, 100 mg/20 ml, and 200 mg/20 ml vials. Treprostinil injection is a prostacyclin mimic that is used to minimise the pace of clinical deterioration in individuals who need to transition from epoprostenol.

According to Dr. Reddy's information about studies proving its effectiveness, patients with NYHA Functional Class II-IV symptoms and aetiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).

Why Purchase the Report?

• To visualize the Global Pulmonary Arterial Hypertension Market segmentation based on the Drug class, Route of Administration, Distribution Channel and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of global pulmonary arterial hypertension market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The Global Pulmonary Arterial Hypertension Market Report Would Provide Approximately 92 Tables, 108 Figures And 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

For more Pharmaceutical related reports, Please Click Here